Clinical trial · Observational
Powered Echelon Device in VATS Surgery
Real World Outcomes of Video-Assisted Thoracoscopic Surgery for Lung Cancer Using ECHELON FLEX™ Powered ENDOPATH® Stapler: a Prospective European Multicenter Study
NCT01808430CI-TRIAL-00016845completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to collect real world outcomes of Video-Assisted Thoracoscopic Surgery (VATS) for lung cancer (lobectomy, wedge resection) using ECHELON FLEX™ Powered ENDOPATH® Staplers 45 mm and/or 60 mm (study devices).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VATS for confirmed non-small cell lung cancer (NSCLC) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- VATS for NSCLC patients
- description
- VATS for confirmed non-small cell lung cancer (NSCLC)
- interventionNames
- Procedure: VATS for confirmed non-small cell lung cancer (NSCLC)
Primary outcomes (1)
- measure
- occurrence and duration of post-operative air leak
- timeFrame
- prolonged air leak defined as longer than 5 days post-op
- description
- occurrence and duration of prolonged air leak defined as longer than 5 days
Secondary outcomes (1)
- measure
- volume of estimated intra-operative blood loss
- timeFrame
- blood loss intra-op and up to 5 days post-op
- description
- volume of estimated intra-operative blood loss
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed NSCLC (up to and including Stage II) for patients undergoing VATS lobectomy. For patients undergoing wedge resection for undiagnosed pulmonary nodule or metastasis from CRC, a malignant diagnosis may be confirmed post-operatively. * Scheduled for lung resection surgery (lobectomy or wedge resection) involving only one lobe of the lung * Willing to give consent and comply with evaluation and treatment schedule * At least 18 years of age Exclusion Criteria: * Active bacterial infection or fungal infection * Systemic administration (intravenous or oral) of steroids (within 30 days prior to study procedure) * Chemotherapy or radiation therapy for lung cancer may not be performed for 30 days prior to the procedure * Scheduled concurrent surgical procedure other than wedge resection or lobectomy (central venous access - e.g. port placement, mediastinoscopy with lymph node sampling, and VATS lymphadenectomy are allowed); * Prior history of VATS or open lung surgery
References
Publications (0)
Data not yet available
No reference posted for this study.